• Breast cancer

Femara Generic Name & Formulations

General Description

Letrozole 2.5mg; tabs.

Pharmacological Class

Aromatase inhibitor.

How Supplied


Femara Indications


In postmenopausal women: Adjuvant treatment of hormone receptor positive early breast cancer; Extended adjuvant treatment of early breast cancer after 5 years of adjuvant tamoxifen therapy; First-line treatment of hormone receptor positive or unknown, locally advanced or metastatic breast cancer; Treatment of advanced breast cancer with disease progression following antiestrogen therapy.

Femara Dosage and Administration


2.5mg once daily. Adjuvant or extended adjuvant therapy: discontinue at tumor relapse; see full labeling. Advanced breast cancer: continue until tumor progression is evident. Severe hepatic impairment or cirrhosis: 2.5mg every other day.


Not established.

Femara Contraindications



Femara Boxed Warnings

Not Applicable

Femara Warnings/Precautions


Monitor bone mineral density, serum cholesterol. Severe renal or hepatic impairment. Embryo-fetal toxicity; exclude pregnancy prior to initiation. Use effective contraception during and for ≥3wks after last dose. Nursing mothers: not recommended (during and for ≥3wks after last dose).

Femara Pharmacokinetics

See Literature

Femara Interactions

Not Applicable

Femara Adverse Reactions

Adverse Reactions

Pain (bone, musculoskeletal, and others), hot flashes, arthralgia, flushing, asthenia, edema, headache, dizziness, hypercholesterolemia, sweating increased, GI upset, fatigue, somnolence, dyspnea, cough, insomnia, hypertension, anorexia, weight changes; thromboembolic or cardio- or cerebrovascular events (rare).

Femara Clinical Trials

See Literature

Femara Note

Not Applicable

Femara Patient Counseling

See Literature